Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России»
https://doi.org/10.14412/1995-4484-2017-474-484
Аннотация
В статье представлены рекомендации по лекарственной терапии аксиальных спондилоартритов, разработанные Экспертной группой по изучению спондилоартритов (ЭкСпА). Рекомендации описывают тактику ведения пациентов в наиболее частых клинических ситуациях, направленную на обеспечение максимальной эффективности и безопасности лечения.
Об авторах
И. З. ГайдуковаРоссия
410012 Саратов, ул. Большая Садовая, 112
А. П. Ребров
Россия
410012 Саратов, ул. Большая Садовая, 112
С. А. Лапшина
Россия
420012 Казань, ул. Бутлерова, 49
Э. Н. Оттева
Россия
680009 Хабаровск, ул. Краснодарская, 9
Т. В. Дубинина
Россия
115522 Москва, Каширское шоссе, 34А
В. В. Бадокин
Россия
125993 Москва, ул. Баррикадная, 2/1
А. Г. Бочкова
Россия
140300 Московская обл., Егорьевск, ул. Рязанская, 50
О. В. Бугрова
Россия
460000 Оренбург, ул. Советская, 6
А. А. Годзенко
Россия
125993 Москва, ул. Баррикадная, 2/1
А. И. Дубиков
Россия
690105 Владивосток, ул. Русская, 76
О. Н. Иванова
Россия
394066 Воронеж, Московский проспект, 151
Т. В. Коротаева
Россия
115522 Москва, Каширское шоссе, 34А
О. Б. Несмеянова
Россия
454092 Челябинск, ул. Воровского, 70
И. П. Никишина
Россия
115522 Москва, Каширское шоссе, 34А
Т. А. Раскина
Россия
650029 Кемерово, ул. Ворошилова, 22а
О. А. Румянцева
Россия
115522 Москва, Каширское шоссе, 34А
А. В. Смирнов
Россия
115522 Москва, Каширское шоссе, 34А
А. В. Ситало
Россия
107078 Москва, ул Новая Басманная, 9/2-4, стр. 6
Ш. Ф. Эрдес
Россия
115522 Москва, Каширское шоссе, 34А
Список литературы
1. Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60 (In Russ.)]. doi: 10.14412/1995-4484-2015-657-660
2. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777-83. doi: 10.1136/ard.2009.108233
3. Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238-42. doi: 10.1136/annrheumdis-2013-203860
4. Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015 Jul;54(7):1200-9. doi: 10.1093/rheumatology/keu461
5. Ward MM. Update on the American College of Rheumatology /Spondyloarthritis Research and Treatment Network / Spondylitis Association of America axial spondyloarhtritis treatment guidelines project. Clin Rheumatol. 2014;33(6):739-40. doi: 10.1007/s10067-014-2660-9
6. Smolen JS, Schö ls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017 Jul 6. doi: 10.1136/annrheumdis-2017-211734
7. Van der Heijde D, Sieper J, Maksymowych WP, et al; Assessment of SpondyloArthritis International Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905- 8. doi: 10.1136/ard.2011.151563
8. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017. doi: 10.1136/annrheumdis-2016- 210770
9. Гайдукова ИЗ, Ребров АП, Шувалова АА. Ремиссия при анкилозирующем спондилите и аксиальных спондилоартритах: современное понимание проблемы. Современная ревматология. 2016;10(1):48-51 [Gaydukova IZ, Rebrov AP, Shuvalova AA. Remission in ankylosing spondylitis and axial spondyloarthritis: A modern understanding of the problem. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(1):48-51 (In Russ.)]. doi: 10.14412/1996-7012-2016-1-48-51
10. Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drugfree remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):807-18. doi: 10.1016/j.berh.2014.10.005
11. Sieper J. How to define remission in ankylosing spondylitis? Ann Rheum Dis. 2012;71 Suppl 2:i93-5. doi: 10.1136/annrheumdis-2011-200798
12. Braun J, Kiltz U, Sarholz M, et al. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Rev Clin Immunol. 2015:1-12. doi: 10.1586/1744666X.2015.1052795
13. Гайдукова ИЗ, Ребров АП, Оттева ЭН и др. Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов). Научно-практическая ревматология. 2016;54(Прил 1):67-74 [Gaidukova IZ, Rebrov AP, Otteva EN, et al. Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthritis, including ankylosing spondylitis, monitoring their efficacy and safety (draft guidelines of the Expert Spondyloarthritis Diagnosis and Treatment Group). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl 1):67-74 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-67-74
14. Лапшина СА, Дубинина ТВ, Бадокин ВВ и др. Ингибиторы фактора некроза опухоли α в лечении аксиальных спондилоартритов (включая анкилозирующий спондилит). Научно-практическая ревматология. 2016;54(Прил 1):75-9 [Lapshina SA, Dubinina TV, Badokin VV, et al. Tumor necrosis factor- α inhibitors in the treatment of axial spondyloarthritis, including ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):75-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-75-79
15. Каратеев АЕ. Комментарий к статье И.З. Гайдуковой и соавт. «Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов)». Научно-практическая ревматология. 2016;54(3):367-9 [Karateev AE. Commentary on the paper «Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthrititides, including ankylosing spondylitis, monitoring their efficacy and safety (draft guidelines of the Expert Spondyloarthritis Diagnosis and Treatment Group)» by I.Z. Gaidukova et al. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):367-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-367-369
16. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of АS. Ann Rheum Dis. 2011;70:896-904. doi: 10.1136/ard.2011.151027896
17. Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 Aug;70(8):1369-74. doi: 10.1136/ard.2010.145995
18. Poddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol. 2012 Jul;24(4):363-9. doi: 10.1097/BOR.0b013e328352b7bd
19. Inman WH. Non-steroidal anti-inflammatory drugs: assessment of risks. Eur J Rheumatol Inflamm. 1987;8(1):71-85.
20. Bennett N, McGonagle D, O’Connor P, et al. Severity of baseline magnetic resonance imaging–evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413-8. doi: 10.1002/art.24024
21. Burd TA, Hughes MS, Anglen JO. Heterotopic ossifi cation prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br. 2003;85:700- 5. doi: 10.1302/0301-620X.85B5.13970
22. Bhattacharyya T, Levin R, Vrahas MS, et al. Nonsteroidal antiinfl ammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum. 2005;53:364-7. doi: 10.1002/art.21170
23. Persson PE, Nilsson OS, Berggren AM. Do non-steroidal anti-infl ammatory drugs cause endoprosthetic loosening? A 10-year follow- up of a randomized trial on ibuprofen for prevention of heterotopic ossification after hip arthroplasty. Acta Orthop. 2005;76:735-40. doi: 10.1080/17453670510045309
24. Gensler L, Reveille J, Lee M, et al. High dose nonsteroidal Anti-Inflammatory drugs (NSAIDs) and tumor necrosis factor Inhibitor Use results in less radiographic progression in Ankylosing Spondylitis – a Longitudinal Analysis [abstract]. Arthritis Rheum. 2016;68 Suppl 10:2481-2.
25. Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1 Suppl 1:e000053. doi: 10.1136/rmdopen-2015-000053
26. Эрдес ШФ, Дубинина ТВ, Румянцева ОА и др. Эволюция аксиального спондилоартрита за 12 месяцев наблюдения когорты КоРСаР. Научно-практическая ревматология. 2016;54(Прил 1):55-9 [Erdes ShF, Dubinina TV, Rumyantseva OA, et al. The evolution of axial spondyloarthritis during 12-month follow-up study of a CoRSaR cohort. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):55-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-55-59
27. Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti- inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23
28. Malfertheiner P, Megraud F, O’Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
29. Chan FK, Graham DY. Review article: prevention of nonsteroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004;19(10):1051-61. doi: 10.1136/ard.2010.128660
30. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non- steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004;19(2):197-208. doi: 10.1111/j.1365-2125.2007.03038
31. Kono Y, Okada H, Takenaka R, et al. Does Helicobacter pylori exacerbate gastric mucosal injury in users of nonsteroidal antiinflammatory drugs? A multicenter, retrospective, case- control study. Gut Liver. 2016 Jan;10(1):69-75. doi: 10.5009/gnl14372
32. Sostres C, Jerusalen Gargallo C, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol. 2014;20(28):9439-50. doi: 10.3748/wjg.v20.i28.9439
33. Greenland P, Alpert JS, Beller GA, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Circulation. 2010;2010(122):e584-e636. doi: 10.1016/j.jacc.2013.11.005
34. Orford JL, Sesso HD, Stedman MA, et al. Comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J. 2002 Jul;144(1):95-100. doi: 10.1067/mhj.2002.123317
35. Tsai WC, Ou TT, Yen JH, et al. Long-term frequent use of nonsteroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015;10(5):e0126347. doi: 10.1371/journal.pone.0126347. eCollection 2015.
36. Ikdahl E, Rollefstad S, Olsen IC, et al. EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic. Biomed Res Int. 2015;2015:515280. doi: 10.1155/2015/515280
37. Heslinga SC, van den Oever IA, van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015;16:80. doi: 10.1186/s12891-015-0532-3
38. Rafaniello C, Ferrajolo C, Sullo MG, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacol Res. 2015 Dec 29;104:108-14. doi: 10.1016/j.phrs.2015.12.026
39. Rosen E, Tsesis I, Vered M. [U.S. Food and Drug Administration (FDA) strengthens warning that non-aspirin non steroidal antiinflammatory drugs (NSAIDs) can cause myocardial infarctions or strokes: the dentist's perspective]. Refuat Hapeh Vehashinayim. 1993;32(4):6-10.
40. Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3):524-33. doi: 10.1161/hypertensionaha.114.05105
41. Ingrasciotta Y, Sultana J, Giorgianni F, et al. Association of individual non-steroidal anti- inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015 Apr 16;10(4):e0122899. doi: 10.1371/journal.pone.0122899.eCollection 2015.
42. Cao YL, Tian ZG, Wang F, et al. Characteristics and clinical outcome of nonsteroidal anti- inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients. World J Gastroenterol. 2014;20(38):13956-65. doi: 10.3748/wjg.v20.i38.13956
43. Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247-55. doi: 10.1177/2050640613502900
44. Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457-68. doi: 10.2147/IJNRD.S39747
45. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71 Suppl 2;i2-45. doi: 10.1136/ard.2010.144998
46. Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011 Jan; 70(1):25-31. doi: 10.1136/ard.2010.133645
47. Lukas C, Landewe R, Sieper J, et al. Development of an ASASendorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Assessment of SpondyloArthritis international Society. Ann Rheum Dis. 2009;68(1):18-24. doi: 10.1136/ard.2008.094870
48. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.
49. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18;4:CD005468. doi: 10.1002/14651858.CD005468.pub2
50. Wu D, Guo YY, Xu NN, et al. Efficacy of anti-tumor necrosis factor therapy for extra- articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 Feb 10;16:19. doi: 10.1186/s12891-015-0489-2
51. Mackay K, Brophy S, Mack C, et al. The development and validation of a radiographic grading system for the hip in Ankylosing Spondylitis: the Bath Ankylosing Spondylitis Radiology Hip Index. J Rheumatol. 2000;27:2866-72.
52. Резюме Совета экспертов «Вопросы “выживаемости” генно-инженерных биологических препаратов и возможности переключения на секукинумаб при анкилозирующем спондилите в реальной клинической практике» Москва, 10 февраля 2017 г. Научно-практическая ревматология. 2017;55(2):230-1 [The Expert Board’s Abstract on Questions of the survival of biological agents and the possibility of switching to secukinumab in ankylosing spondilitis in real clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):230-1 (In Russ.)]. doi: 10.14412/1995-4484-2017-230-231
53. Arends S, Lebbink HR, Spoorenberg A, et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010;28(5):661-8. doi: 10.1186/ar3369
54. Plasencia C, Pascual-Salcedo D, Nuno L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828
55. Murdaca G, Spano F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43-52. doi: 10.1517/14740338.2016.1112375
56. Гайдукова ИЗ, Ребров АП, Апаркина АВ, Хондкарян ЭВ. Концентрация интерлейкина-17а остается стабильно высокой у больных анкилозирующим спондилитом, получающих ингибиторы фактора некроза опухоли α в течение года. Терапевтический архив. 2017;89(4):80-5 [Gaydukova IZ, Rebrov AP, Aparkina AV, Khondkaryan EV. Stable high interleukin-17A concentration in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitors during a year. Therapevticheskyy Archiv. 2017;89(4):80-5 (In Russ)]. doi: 10.17116/terarkh201789480-85
57. Cantini F, Niccoli L, Cassara E, et al. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow- upstudy. Biologics. 2013;7:1-6. doi: 10.2147/BTT.S31474
58. Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015;33(2):174-80.
59. Olivieri I, D’Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev. 2013 May;12(7):691-3. doi: 10.1016/j.autrev.2012.08.013
60. Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol. 2013 Jul-Aug;31 4 Suppl 78:S37-42.
61. Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). 2010;49(6);1107-11. doi: 10.1016/S0140-6736(17)30068-5
62. Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol. 2013;31 Suppl 78:S33-6.
63. Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2017 May;18:1-23. doi: 10.1080/09546634.2017.1329511
64. Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066
65. Accortt NA, Bonafede MM, Collier DH, et al. Risk of subsequent infection among patients receiving tumor necrosis factor inhibitors and other disease-modifying antirheumatic drugs. Arthritis Rheum. 2016;68(1):67-76. doi: 10.1002/art.39416
66. Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15 Supp1:11-34. doi: 10.1080/14740338.2016.1240783
67. Ooka K, Lim JK. Treatment of hepatitis C in patients undergoing immunosuppressive drug therapy. J Clin Transl Hepatol. 2016 Sep 28;4(3):206-27. doi: 10.14218/JCTH.2016.00017
68. Valaydon Z, Pellegrini M, Thompson A, et al. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunol. 2016;5(12):e115. doi: 10.1038/cti.2016.68
69. Белов БС. Терапия генно-инженерными биологическими препаратами и инфекции у больных ревматоидным артритом: актуальность и перспективы. Научно- практическая ревматология. 2014;52(3):322-30 [Belov BS. Biological therapy and infections in patients with rheumatoid arthritis: relevance and prospects. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):322-30 (In Russ.)]. doi: 10.14412/1995-4484-2014-322-330
70. Wangsiricharoen S, Ligon C, Gedmintas L, et al. The rates of serious infections in HIV- infected patients who received tumor necrosis factor (TNF)-α inhibitor therapy for concomitant autoimmune diseases. Arthritis Care Res (Hoboken). 2017;69(3):449-52. doi: 10.1002/acr.22955
71. Aboulafia DM, Bundow D, Wilske K, Ocas UI. Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis. Mayo Clin Proc. 2000;75:1093-8. doi: 10.4065/75.10.1093
72. Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol. 2008 Apr;144(4):453-6. doi: 10.1001/archderm.144.4.453
73. Cepeda EJ, Williams FM, Ishimori MLet al. The use of antitumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008;67:710-2. doi: 10.1136/ard.2007.081513
74. Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016 May;74(5):974-80. doi: 10.1016/j.jaad.2015.11.043. Epub 2016 Jan 14.
75. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004;18:257-64. doi: 10.1016/j.jaad.2015.11.043
76. Solomon DH, Mercer E, Kavanaugh A. Observational Studies on the Risk of Cancer Associated with TNF-Inhibitors in RA: A Review of their Methodologies and Results. Arthritis Rheum. 2012;64(1):21-32. doi: 10.1002/art.30653
Рецензия
Для цитирования:
Гайдукова И.З., Ребров А.П., Лапшина С.А., Оттева Э.Н., Дубинина Т.В., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Годзенко А.А., Дубиков А.И., Иванова О.Н., Коротаева Т.В., Несмеянова О.Б., Никишина И.П., Раскина Т.А., Румянцева О.А., Смирнов А.В., Ситало А.В., Эрдес Ш.Ф. Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474-484. https://doi.org/10.14412/1995-4484-2017-474-484
For citation:
Gaidukova I.Z., Rebrov A.P., Lapshina S.A., Otteva E.N., Dubinina T.V., Badokin V.V., Bochkova A.G., Bugrova O.V., Godzenko A.A., Dubikov A.I., Ivanova O.N., Korotaeva T.V., Nesmeyanova O.B., Nikishina I.P., Raskina T.A., Rumyantseva O.A., Smirnov A.V., Sitalo A.V., Erdes Sh.F. USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND BIOLOGICAL AGENTS FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIDES. RECOMMENDATIONS OF THE SPONDYLOARTHRITIS STUDY GROUP OF EXPERTS, ALL-RUSSIAN PUBLIC ORGANIZATION «THE ASSOCIATION OF RHEUMATOLOGY OF RUSSIA». Rheumatology Science and Practice. 2017;55(5):474-484. (In Russ.) https://doi.org/10.14412/1995-4484-2017-474-484